Laboratory results of liver function and metabolic function 6 months after LT were compared. Blood samples following 12 h fasting and 2 h after dinner were drawn from vein for adrenocorticotropic hormone (ACTH), cortisol, glucose, and serum lipids (total cholesterol, LDL, HDL, and triglyceride). ACTH was tested by electrochemiluminescence Elecsys ACTH immunoassay, ECLIIA, (Roche Diagnostics, Mannheim, Germany) on E170 Model. Cortisol was tested by a chemiluminescence assay (Bayer, Shanghai, China) on the ACS180 SE Model. The biochemistry exams were done by automated chemistry analyzer (Hitachi, Tokyo, Japan) on Hitachi 7600-110 Model. The liver function and lipids were tested by BECKMAN COULTER analyzer (Beckman Coulter Diagnostics, CA, USA) on AU5811 Model.
We measured the new onset diabetes according to the American Diabetes Association/World Health Organization guidelines; new onset DM was defined as patient used to have a normal fasting blood glucose, but after liver transplantation, he/she has a fasting blood glucose of ≥7.00 mmol/L (1.26 g/L) confirmed on at least 2 occasions or current treatment with an oral antidiabetic drug or insulin. The pathological slides from the biopsy were parallel to the liver function results.
We measured the new onset diabetes according to the American Diabetes Association/World Health Organization guidelines; new onset DM was defined as patient used to have a normal fasting blood glucose, but after liver transplantation, he/she has a fasting blood glucose of ≥7.00 mmol/L (1.26 g/L) confirmed on at least 2 occasions or current treatment with an oral antidiabetic drug or insulin. The pathological slides from the biopsy were parallel to the liver function results.